NASDAQ: NRBO - NeuroBo Pharmaceuticals, Inc.

Yield per half year: +981.63%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review The stock's return over the last year (636.11%) is higher than the sector average (-92.75%).
  • Positive review Current debt level 0% is below 100% and has decreased over 5 years from 47.92%.

Disadvantages

  • Negative review Price (5.3 $) is higher than fair price (4.74 $)
  • Negative review Dividends (0%) are below the sector average (1.8636%).
  • Negative review The company's current efficiency (ROE=-33.65%) is lower than the sector average (ROE=12.96%)

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

NeuroBo Pharmaceuticals, Inc. Healthcare Index
7 days -0.9% -93.6% 2.5%
90 days 1132.6% -93.3% 5.7%
1 year 636.1% -92.7% 46.1%

Positive review NRBO vs Sector: NeuroBo Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 728.86% over the past year.

Positive review NRBO vs Market: NeuroBo Pharmaceuticals, Inc. has outperformed the market by 590.01% over the past year.

Negative review Highly volatile price: NRBO is significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of more than +/- 15% per week.

Long period: NRBO with weekly volatility of 12.23% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 0

3.2. Revenue

EPS -2.38
ROE -33.65%
ROA -24.3%
ROIC 0%
Ebitda margin 0%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review company.analysis.fundamental.minus11_title: The current price (5.3 $) is higher than the fair price (4.74 $).

Negative review Price is higher than fair: The current price (5.3 $) is 10.6% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (49.49).

Positive review P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (151.31).

4.2.1 P/E Similar companies

4.3. P/BV

Positive review P/BV vs Sector: The company's P/BV (0.0962) is lower than that of the sector as a whole (4.89).

Positive review P/BV vs Market: The company's P/BV (0.0962) is lower than that of the market as a whole (13.37).

4.3.1 P/BV Similar companies

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (5.37).

Positive review P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (25.9).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (2.72) is lower than that of the sector as a whole (16.27).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (2.72) is lower than that of the market as a whole (80.44).


5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Negative review Yield Trend: Negative and has fallen by -8.93% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (-15.11%) is below the 5-year average return (-8.93%).

Negative review Profitability vs Sector: The return for the last year (-15.11%) is lower than the return for the sector (163.81%).

5.4. ROE

Negative review ROE vs Sector: The company's ROE (-33.65%) is lower than that of the sector as a whole (12.96%).

Negative review ROE vs Market: The company's ROE (-33.65%) is lower than that of the market as a whole (9.86%).

5.5. ROA

Negative review ROA vs Sector: The company's ROA (-24.3%) is lower than that of the sector as a whole (7.44%).

Negative review ROA vs Market: The company's ROA (-24.3%) is lower than that of the market as a whole (6.05%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (13.31%).

Negative review ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (0%) is quite low in relation to assets.

Positive review Debt reduction: over 5 years, the debt has decreased from 47.92% to 0%.

Negative review Excess of debt: The debt is not covered by net income, percentage 0%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.8636%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Negative review Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Positive review Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet